company background image
ALECR logo

Eurofins-Cerep ENXTPA:ALECR Stock Report

Last Price

€22.20k

Market Cap

€112.0m

7D

0%

1Y

-20.7%

Updated

14 Jul, 2024

Data

Company Financials

ALECR Stock Overview

Provides various drug discovery services to pharmaceutical, biopharmaceutical, and biotechnology companies France and internationally.

ALECR fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance2/6
Financial Health4/6
Dividends0/6

Rewards

Risk Analysis

No risks detected for ALECR from our risk checks.

Eurofins-Cerep SA Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Eurofins-Cerep
Historical stock prices
Current Share Price€22,200.00
52 Week High€29,200.00
52 Week Low€20,000.00
Beta0.61
11 Month Change0%
3 Month Change1.83%
1 Year Change-20.71%
33 Year Change64.44%
5 Year Change276.27%
Change since IPO374.87%

Recent News & Updates

Eurofins-Cerep SA's (EPA:ALECR) Subdued P/S Might Signal An Opportunity

Jun 26
Eurofins-Cerep SA's (EPA:ALECR) Subdued P/S Might Signal An Opportunity

Eurofins-Cerep SA (EPA:ALECR) Screens Well But There Might Be A Catch

Sep 28
Eurofins-Cerep SA (EPA:ALECR) Screens Well But There Might Be A Catch

Recent updates

Eurofins-Cerep SA's (EPA:ALECR) Subdued P/S Might Signal An Opportunity

Jun 26
Eurofins-Cerep SA's (EPA:ALECR) Subdued P/S Might Signal An Opportunity

Eurofins-Cerep SA (EPA:ALECR) Screens Well But There Might Be A Catch

Sep 28
Eurofins-Cerep SA (EPA:ALECR) Screens Well But There Might Be A Catch

Shareholder Returns

ALECRFR Life SciencesFR Market
7D0%2.7%0.7%
1Y-20.7%-11.2%-0.3%

Return vs Industry: ALECR underperformed the French Life Sciences industry which returned -11.2% over the past year.

Return vs Market: ALECR underperformed the French Market which returned -0.3% over the past year.

Price Volatility

Is ALECR's price volatile compared to industry and market?
ALECR volatility
ALECR Average Weekly Movement5.1%
Life Sciences Industry Average Movement6.2%
Market Average Movement4.7%
10% most volatile stocks in FR Market9.4%
10% least volatile stocks in FR Market2.6%

Stable Share Price: ALECR has not had significant price volatility in the past 3 months.

Volatility Over Time: ALECR's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1989228Damien Vielliardwww.eurofins.fr/cerep/

Eurofins-Cerep SA provides various drug discovery services to pharmaceutical, biopharmaceutical, and biotechnology companies France and internationally. The company’s research services include compound management, and high-throughput screening and profiling. The company was formerly known as Cerep SA and changed its name to Eurofins-Cerep SA in June 2014.

Eurofins-Cerep SA Fundamentals Summary

How do Eurofins-Cerep's earnings and revenue compare to its market cap?
ALECR fundamental statistics
Market cap€111.98m
Earnings (TTM)€7.64m
Revenue (TTM)€44.07m

14.7x

P/E Ratio

2.5x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ALECR income statement (TTM)
Revenue€44.07m
Cost of Revenue€23.86m
Gross Profit€20.21m
Other Expenses€12.57m
Earnings€7.64m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)1.51k
Gross Margin45.86%
Net Profit Margin17.33%
Debt/Equity Ratio0.005%

How did ALECR perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.